IEA's "Smokefree 2030 Plan" Encourages Low-Risk Alternatives to Cigarettes

Nov.03.2022
IEA's "Smokefree 2030 Plan" Encourages Low-Risk Alternatives to Cigarettes
A new report from IEA suggests using e-cigarettes and other safer alternatives to reduce smoking rates in the UK.

Prior to the parliamentary debate on the independent review of the Smoke-Free 2030 policy on November 3rd, the Institute of Economic Affairs (IEA) released an alternative strategy aimed at reducing smoking rates in the UK, called the "Smoke-Free 2030 Plan B.


This approach is in stark contrast to the recent Khan review, which suggested gradually phasing out the sale of cigarettes over time. The report's author, Christopher Snowdon, believes that as long as there is demand - with only 53% of UK smokers stating they want to quit - a ban on smoking will lead to black market activity, crime, and poverty without eradicating smoking.


Christopher Snowdon, as reported by tobaccoreporter.


A new plan to aid smoking cessation has been proposed, highlighting the success of electronic cigarettes and other safer alternatives. According to data from the IEA, in the UK, 9.3% of adults now use e-cigarettes, causing smoking rates to drop from 20% in 2012 to 14%. In the EU, where only 2% of adults use e-cigarettes, smoking rates declined by only 1% from 2014 to 2020. As of this year, 28% of smokers have never attempted to use e-cigarettes, so removing barriers to access low-risk nicotine alternatives is crucial.


The Head of Lifestyle Economics at the IEA, Christopher Snowdon, has advised the government to address widespread misinformation about the risks of e-cigarettes. Currently, 40% of smokers in the UK incorrectly believe that nicotine causes cancer. Furthermore, between 2014 and 2020, the proportion of smokers who incorrectly perceived e-cigarettes to be as dangerous or more dangerous than smoking increased from 36% to 53%. The conclusions drawn by the Royal College of Physicians suggest that the long-term risks of e-cigarette use are "unlikely to exceed 5% of those associated with smoking". The government should ensure that public health agencies promote the benefits of e-cigarettes relative to smoking.


Edward Snowden also suggested that the government should accept the freedom offered by Brexit to reform the Tobacco Products Directive (TPD). Article 20 of the TPD contains punitive regulations for e-cigarettes, covering everything from advertising to the size of refillable vape tanks. According to Snowden, reducing these burdensome regulations will remove significant barriers to entry.


Smokers can be encouraged to quit by reducing the burdensome regulations on alternative low-risk tobacco products such as heated tobacco and nicotine pouches. These products are subject to overly strict regulations, with snuff being banned in the UK.


According to the IEA, the UK has generally exercised wise regulation of e-cigarettes. However, the think tank believes that with more emphasis on promoting the switch to low-risk tobacco alternatives and relaxing relevant regulatory frameworks, smoking may truly become a thing of the past.


The government's plan to reduce smoking rates to 5% by 2030 is highly unlikely to be achieved without a significant shift towards low-risk alternatives, according to Snowden. Fortunately, there are more and more alternatives available. The government needs to create a regulatory environment that allows these alternatives to thrive and ensures that smokers are not misled by fake news. There are a number of simple, low-cost reforms that could help the government reach its health goals without persecuting smokers.


Statement:


This article is compiled from third-party information and is intended solely for industry exchange and learning purposes.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the truth or accuracy of the article's content. The translation of this article is only intended for industry communication and research purposes.


Due to limitations in translation proficiency, the translated article may not fully express the same meaning as the original text. Please refer to the original text for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on all domestic, Hong Kong/Macau/Taiwan-related, and foreign-related statements and positions.


The compilation of information is the property of the original media and author. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
Cliff Douglas, a veteran U.S. tobacco-control and public health policy figure, told NAS 2026 that the “continuum of risk” should play a central role in tobacco policy. He called for clearer market pathways, stronger risk communication, differentiated regulation and enforcement, and said possible FDA reforms to PMTA reviews could be a “welcome correction” if they create a more efficient, predictable route for scientifically substantiated lower-risk products. Read 2Firsts’ on-site coverage.
Sep.26
Product | Philip Morris Japan Launches Ginza-Exclusive IQOS ILUMA i PRIME, Limited to 1,814 Units at First Global Flagship
Product | Philip Morris Japan Launches Ginza-Exclusive IQOS ILUMA i PRIME, Limited to 1,814 Units at First Global Flagship
Philip Morris Japan (PMJ) launched the IQOS ILUMA i PRIME Ginza Limited Model Set in Tokyo on September 4, 2026, alongside the opening of IQOS Flagship Ginza, the brand’s first global flagship store. The Oasis Blue edition is limited to 1,814 individually numbered units, with the figure derived from the store’s address at Ginza 1-8-14. The set also includes two Yamanaka-nuri glasses and special packaging, priced at JPY 11,980 and sold exclusively at the Ginza flagship.
Sep.07
China Tobacco Yunnan files patent for cellulose-free nicotine pouch scaffold to replace microcrystalline cellulose
China Tobacco Yunnan files patent for cellulose-free nicotine pouch scaffold to replace microcrystalline cellulose
China Tobacco Yunnan Industrial Co., Ltd. has filed a patent application for a cellulose-free scaffold material for nicotine pouches, proposing a combination of bioceramic material, polydextrose and sugar alcohols to replace conventional microcrystalline cellulose and cellulose derivatives. The filing aims to address issues including powdery mouthfeel, residue and limited release control, while also reducing reliance on existing cellulose-based patent portfolios. In patent examples, one fast-release formulation reached a nicotine release rate of 50% at 10 minutes and more than 90% at 20 minutes.
Sep.02
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
2Firsts reviewed the original federal court complaint filed by Altria subsidiaries Helix Innovations and NJOY on Sept. 2 challenging FDA’s 2021 PMTA rule. The lawsuit questions whether FDA’s review process complies with the Tobacco Control Act’s 180-day timeline, even as the agency moves to accelerate PMTA reviews and issues more marketing orders. Drawing on the complaint, FDA records, government audits and recent court rulings, 2Firsts examines the legal arguments, supporting evidence and potential implications for the U.S. tobacco review system.
Regulations
Sep.03
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
FDA’s Center for Tobacco Products detailed new PMTA review data and process changes at the 2026 FDLI conference. Pending PMTAs fell from about 450,000 at the start of 2025 to 135,000 by September 2026. CTP also discussed its 180-day review goal, current sPMTA pilot, alternate-supplier planning, more than 50,300 pending SE reports, and lessons from the nicotine pouch pilot already being applied to ENDS review.
Regulations
Oct.07
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
At the 2026 New Approaches Summit in New York, FDA Center for Tobacco Products Director Bret Koplow said the PMTA pathway is “predicated on tobacco harm reduction.” He outlined four CTP priorities: youth prevention, helping adults quit or switch to lower-risk products, improving relative-risk communication, and reducing unauthorized products. Koplow also addressed flavored e-cigarettes, public risk perceptions, industry credibility and efforts to make PMTA reviews more efficient and predictable.
Sep.26